Danièle Bentué-Ferrer

Summary

Country: France

Publications

  1. doi [Therapeutic drug monitoring of valproate]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:233-40. 2010
  2. pmc Impaired cognition and attention in adults: pharmacological management strategies
    Herve Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Pôle des Neurosciences de Rennes, Faculte de Medecine, Universite de Rennes I, France
    Neuropsychiatr Dis Treat 3:103-16. 2007
  3. doi [Therapeutic drug monitoring of topiramate]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:17-22. 2010
  4. doi [Therapeutic drug monitoring of lamotrigine]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:39-46. 2010
  5. ncbi Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie, Faculte de Medecine, Rennes, France
    CNS Drugs 17:947-63. 2003
  6. doi [Therapeutic drug monitoring of pregabaline]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:47-9. 2010
  7. doi [Therapeutic drug monitoring of tiagabine]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:51-5. 2010
  8. doi [Therapeutic drug monitoring of clobazam]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:225-31. 2010
  9. doi [Therapeutic drug monitoring of vigabatrin]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:23-7. 2010
  10. ncbi Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers
    Stéphane Schück
    Laboratoire de Pharmacologie Experimentale et Clinique, Université de Rennes I Faculté de Médecine, CS 34317, 35 043 Rennes cedex, France
    Fundam Clin Pharmacol 16:57-65. 2002

Collaborators

Detail Information

Publications37

  1. doi [Therapeutic drug monitoring of valproate]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:233-40. 2010
    ..The therapeutic range is from 50 to 100 mg/L (346-693 micromol/L). The level of proof of the interest of the TDM for this molecule was estimated in: recommended...
  2. pmc Impaired cognition and attention in adults: pharmacological management strategies
    Herve Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Pôle des Neurosciences de Rennes, Faculte de Medecine, Universite de Rennes I, France
    Neuropsychiatr Dis Treat 3:103-16. 2007
    ..Drug therapeutic strategies" for improving cognition (except for memory function) are currently rather scarce, but promising perspectives for a new neurobiological approach to cognitive pharmacology will be highlighted...
  3. doi [Therapeutic drug monitoring of topiramate]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:17-22. 2010
    ..For this molecule, the level of proof of the interest of the TDM was estimated in: possibly useful...
  4. doi [Therapeutic drug monitoring of lamotrigine]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:39-46. 2010
    ..The correlation concentration-toxicity is better argued. The recommended therapeutic range is from 2.5 to 15 mg/L. For this molecule, the level of proof of the interest of the TDM was estimated in: possibly useful...
  5. ncbi Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie, Faculte de Medecine, Rennes, France
    CNS Drugs 17:947-63. 2003
    ..Possible interactions involving other often coprescribed antidementia agents (e.g. memantine, antioxidants, cognitive enhancers) remain an open area requiring particularly prudent use...
  6. doi [Therapeutic drug monitoring of pregabaline]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:47-9. 2010
    ..For this molecule, the level of proof of the interest of TDM was estimated in: remaining to estimate...
  7. doi [Therapeutic drug monitoring of tiagabine]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:51-5. 2010
    ..In patients treated with therapeutic dose, serum levels are between 20 and 100 microg/L (50-250 nmol/L). For this molecule, the level of proof of the interest of TDM was estimated in: remaining to estimate...
  8. doi [Therapeutic drug monitoring of clobazam]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:225-31. 2010
    ..The level of proof of the interest of the Therapeutic Drug Monitoring for this molecule is estimated in: rather useless...
  9. doi [Therapeutic drug monitoring of vigabatrin]
    Danièle Bentué-Ferrer
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:23-7. 2010
    ..For this molecule, the level of proof of the interest of the TDM was estimated in: to be useless...
  10. ncbi Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers
    Stéphane Schück
    Laboratoire de Pharmacologie Experimentale et Clinique, Université de Rennes I Faculté de Médecine, CS 34317, 35 043 Rennes cedex, France
    Fundam Clin Pharmacol 16:57-65. 2002
    ..It is concluded that a single intravenous perfusion of piribedil 3 mg improves alertness and the information processing speed within the central nervous system, in healthy volunteers...
  11. doi [Therapeutic drug monitoring of stiripentol]
    Marie Clémence Verdier
    CHU Pontchaillou, Laboratoire de Pharmacologie Biologique, Rennes, France
    Therapie 67:157-60. 2012
    ..However, because of its non-linear kinetics, stiripentol should be a good candidate for therapeutic drug monitoring (TDM). Nonetheless, the current level of evidence for the advantage of TDM is "remains to be estimated"...
  12. doi [Therapeutic drug monitoring of lacosamide]
    Danièle Bentué-Ferrer
    CHU Pontchaillou, Laboratoire de Pharmacologie Biologique, Rennes, France
    Therapie 67:151-5. 2012
    ..The potential for drug-drug interaction of lacosamide is low and variability between individuals is minimal. Accordingly, the level of evidence for the therapeutic drug monitoring has been estimated at "probably of no use"...
  13. doi [Therapeutic drug monitoring of gabapentin]
    Olivier Tribut
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:57-60. 2010
    ..During clinical studies, the plasma concentrations of gabapentin were generally included between 2 and 20 mg/L. For this molecule, the level of proof of the interest of therapeutic drug monitoring was estimated in: possibly useful...
  14. ncbi Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg
    Herve Allain
    Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, 2, avenue du professeur Leon Bernard, 35043 Rennes, CS34317, France
    Hum Psychopharmacol 18:369-74. 2003
    ..Insomniac patients tended to prefer zolpidem to zaleplon on both nocturnal and diurnal assessments. These results provide additional information for the physician's choice, based on the patient's preference for a given drug...
  15. ncbi Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography
    Olivier Tribut
    Laboratoire de Pharmacologie Biologique, Hopital de Pontchaillou, Rennes, France
    Ther Drug Monit 24:554-62. 2002
    ..The method has been validated extensively and has been in routine use in our laboratory for several months for drug monitoring in plasma samples from patients treated with antiretroviral drugs...
  16. doi [Therapeutic drug monitoring of felbamate]
    Olivier Tribut
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:35-8. 2010
    ..Potentially fatal side effects can be caused by felbamate (aplastic anemia, acute liver failure), which limits its use because they are dose-independant...
  17. doi [Therapeutic drug monitoring of zonisamide]
    Marie Clémence Verdier
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 65:29-34. 2010
    ..A specific monitoring of patient is recommended in renal impairment. For this molecule, the interest of TDM has been evaluated: possibly useful...
  18. ncbi Alzheimer's disease: the pharmacological pathway
    Herve Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, CS 34317, 35043 Rennes Cedex, France
    Fundam Clin Pharmacol 17:419-28. 2003
    ..The rapidity at which these compounds will be at our disposal is highly dependent on the policy of the pharmaceutical companies...
  19. ncbi Does rat global transient cerebral ischemia serve as an appropriate model to study emotional disturbances?
    Guy Bernard Bantsiele
    Laboratoire de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, CS34317, 35043 Rennes, France
    Fundam Clin Pharmacol 18:685-92. 2004
    ....
  20. ncbi Treatment of the mild cognitive impairment (MCI)
    Herve Allain
    Laboratory of Experimental and Clinical Pharmacology and Centre Mémoire Ressources Recherche de Bretagne, Faculte de Medecine, 2 Avenue du Professeur Leon Bernard, Rennes Cedex, France
    Hum Psychopharmacol 22:189-97. 2007
    ..These three hypotheses will be presented on the basis of the neurobiology and the pharmacology, and examples of potentially active candidates will be discussed...
  21. ncbi [Level of evidence for therapeutic drug monitoring of low dose methotrexate in inflammatory diseases]
    Marie Clémence Verdier
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 66:63-72. 2011
    ..But currently, the level of proof of the therapeutic drug monitoring of low dose methotrexate in inflammatory disease was classified "remaining to evaluate"...
  22. pmc Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring
    Marie Clémence Verdier
    Laboratoire de Pharmacologie Biologique, Hopital de Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France
    Antimicrob Agents Chemother 55:4873-9. 2011
    ..This technique is easy to use in routine therapeutic drug monitoring of beta-lactam antibiotics...
  23. doi [Pharmacologic treatment of insomnia in children and adolescent psychiatric patients]
    Claire Chevreuil
    Service de psychiatrie infanto juvénile, CH Guillaume Regnier, Rennes, France
    Therapie 65:1-12. 2010
    ....
  24. doi Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application
    Marie Clémence Verdier
    Biological Pharmacology and Toxicology, University Hospital, Rennes 1 University, Rennes, France
    Clin Chem Lab Med 49:69-75. 2011
    ....
  25. ncbi Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0
    Cecile Loichot
    Laboratoire de Pharmacologie, Hopitaux Universitaires, Strasbourg, France
    Fundam Clin Pharmacol 20:91-6. 2006
    ....
  26. ncbi The anti-dementia drugs: myth, hype or reality?
    Herve Allain
    Laboratoire de Pharmacologie Expérimentale et Clinique et Centre Mémoire Ressources Recherche, Faculte de Medecine, Universite de Rennes I, Rennes, France
    Curr Opin Neurol 16:S23-7. 2003
    ..It remains for clinicians to confirm the authenticity of this worldwide project...
  27. ncbi [What is dementia? 5. "Anti-dementia" drug: myth or reality?]
    Herve Allain
    Laboratoire de pharmacologie expérimentale et clinique et centre mémoire ressources recherche CMRR, Faculte de Medecine, Universite de Rennes I
    Psychol Neuropsychiatr Vieil 1:151-6. 2003
    ..The present targets of pharmacology are directed against the decline of the neurone and of cognitive performance. Clinicians will check the accuracy of this very ambitious project...
  28. ncbi Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma
    Olivier Tribut
    Laboratoire de Pharmacologie, Hopital de Pontchaillou, 35033 Rennes, France
    Ther Drug Monit 27:265-9. 2005
    ..This method has been in routine use in our laboratory for antiretroviral drug monitoring and now allows quantitative assay of a novel HIV protease inhibitor, atazanavir, with satisfactory intra- and interassay precision (CV<12%)...
  29. ncbi Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids
    Herve Allain
    Service de Pharmacologie, Faculte de Medecine, Universite de Rennes 1, Rennes, France
    Drug Saf 27:649-60. 2004
    ..Such a review reinforces the need for a strong international pharmacovigilance organisation using similar methods to detect and analyse the adverse effects of drugs...
  30. doi [Therapeutic drug monitoring of quinine]
    Marie Clémence Verdier
    Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France
    Therapie 66:507-16. 2011
    ..For this compound, the level of evidence of the interest of therapeutic drug monitoring has been evaluated and the latter is recommended...
  31. ncbi [Aripiprazole use in children and adolescent psychiatric patients]
    Claire Chevreuil
    Service de psychiatrie infanto juvénile, CH Guillaume Regnier, Rennes, France
    Therapie 66:123-30. 2011
    ..Aripiprazole appears to be an alternative for children and adolescents who are vulnerable to these side effects and are having trouble coping with them...
  32. ncbi [Pharmacological treatment in severe dementia]
    Pierre Jouanny
    centre mémoire de ressource et de recherche, Universite de Rennes I, France
    Psychol Neuropsychiatr Vieil 3:S51-5. 2005
    ..Medical treatment should only be co-prescribed with a global care of all co-morbidities, autonomy loss and patient's and care-giver's burden, and associated with psychological and organisational support...
  33. doi Subthalamic nucleus modulates social and anxogenic-like behaviors
    Jean Michel Reymann
    Universite de Rennes 1, Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, France
    Behav Brain Res 252:356-62. 2013
    ..These results highlight another level of complexity of the behavioral changes after stimulation. ..
  34. ncbi Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo
    Herve Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Universite de Rennes 1, Faculte de Medecine, 2 rue du Pr Léon Bernard, CS 34317, 35043 Rennes Cedex, France
    Eur J Clin Pharmacol 59:179-88. 2003
    ..e. usual starting doses in elderly) or placebo were administered at night to 48 healthy elderly volunteers aged 65 years or more. The study included four treatment periods separated by wash-out periods of at least 1 week...
  35. doi [Therapeutic drug monitoring of ethosuximide]
    Danièle Bentué-Ferrer
    CHU Pontchaillou, Laboratoire de Pharmacologie Biologique, Rennes, France
    Therapie 67:391-6. 2012
    ..Despite these arguments and due to the lack of studies providing a sufficient level of evidence, the recommendation can only be "potentially useful", assessment probably underestimated...
  36. doi Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma
    Marie Clémence Verdier
    Biological Pharmacology and Toxicology, University Hospital, Rennes 1 University, Rennes, France
    Clin Chem Lab Med 48:1515-22. 2010
    ....
  37. ncbi Disease-modifying drugs and Parkinson's disease
    Herve Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, 2 Av du Pr Leon Bernard, F 35043 Rennes, France
    Prog Neurobiol 84:25-39. 2008
    ..It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases...